Anti Amyloid Leqembi denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Leqembi — and How to Navigate It Successfully

Prior authorization (PA) for Leqembi (lecanemab) is a standard gatekeeper step at Aetna, as it is for most high-cost specialty biologics. The PA process is not a denial on the merits — it is a procedural requirement that gives Aetna the opportunity to verify that your diagnosis, amyloid confirmation, and clinical profile align with the FDA-approved indication and Aetna's coverage criteria. A thorough, well-organized PA submission resolves most of these cases without requiring a formal appeal.

## Why Prior Authorization Is Required

Aetna requires PA for Leqembi to confirm that the patient has early symptomatic Alzheimer's disease, that amyloid pathology has been established through an accepted diagnostic method, and that the prescriber is an appropriate specialist. PA also allows Aetna to verify that the request is consistent with the FDA-approved indication before authorizing a high-cost infusion series. A denial at the PA stage most often means a documentation gap rather than a clinical eligibility problem.

## Federal Appeal Rights After a PA Denial

• Internal appeal (ACA §2719 / ERISA §503): A PA denial is a coverage adverse action and triggers full appeal rights. File a written appeal within the timeframe on the denial notice. The appeal must be reviewed under a full-and-fair standard by a qualified clinical reviewer not involved in the original PA determination.
• Expedited appeal: If your neurologist certifies that waiting for standard review poses a serious risk to your health, request expedited internal review (72-hour Aetna response) and simultaneously request expedited external review.
• External review: After a final internal denial, you have approximately four months to request independent external review. PA denials for FDA-approved drugs are frequently reversed at the external-review stage when the clinical record is complete. IRO decisions bind Aetna.

## Documentation to Gather

1. Specialist diagnosis note — A neurologist's note explicitly confirming early symptomatic Alzheimer's disease with clinical detail on staging and functional status. 2. Amyloid confirmation report — PET imaging result or CSF biomarker analysis confirming amyloid pathology, dated, with the interpreting physician's conclusion. 3. Cognitive and functional assessments — Standardized test results from the chart showing current cognitive and functional status. 4. Prior Alzheimer's treatment history — Dates, regimens, and outcomes for any previously prescribed Alzheimer's treatments, relevant if Aetna's policy requires prior therapy. 5. Prescriber medical-necessity letter — The most critical document. The neurologist should walk through each of Aetna's PA criteria explicitly and cite the specific chart evidence satisfying each one. 6. Aetna's current PA criteria for Leqembi — Obtain this before submitting the PA so the submission addresses every listed requirement.

## Criteria-Mapping Structure

For each criterion in Aetna's PA policy, include a direct response in the medical-necessity letter:

| Aetna PA Criterion | FDA Label Alignment | Chart Evidence | |---|---|---| | Early symptomatic AD confirmed | Approved indication | Specialist note + ICD-10 | | Amyloid pathology confirmed | Label requirement | PET or CSF report | | Clinical staging within approved range | Per FDA label | Assessment results in chart | | Prescriber is appropriate specialist | Per Aetna policy | Neurologist credentials + NPI | | Any required prior therapy | Per Aetna policy | Treatment history with dates/outcomes |

After submitting, track the response deadline and follow up in writing if Aetna does not respond within the regulatory timeframe.